Publiora

Menghubungkan ke Publiora...

Publiora

Cost-efeectivinees analysisis and blood glucose reduction profile of metformin and glimepirid use of type 2 diabetes melitus patient at RSUD R. Syamsudin, SH

Honifa HonifaProgram Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Pakuan, Bogor, Jawa Barat, IndonesiaNisa Najwa Rokhmah Program Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Pakuan, Bogor, Jawa Barat, IndonesiaOktaviana ZunnitaProgram Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Pakuan, Bogor, Jawa Barat, IndonesiaElina ElinaProgram Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Pakuan, Bogor, Jawa Barat, Indonesia
Journal Pharmaceutical And Sciences (Sinta 3)No. 1 (2025)12 Januari 2025hal. 42-50
DOI10.36490/journal-jps.com.v8i1.600

Abstrak

Hyperglycemia caused by abnormalities in insulin secretion and insulin function is a hallmark of a metabolic disorder known as diabetes mellitus (DM). The choice of alternative medications for DM varies significantly, making it essential to consider cost to ensure that the selected drug remains affordable while providing the best therapeutic effect. The purpose of this study is to examine the glucose-lowering profile and identify the most cost-effective antidiabetic drug for use in type 2 diabetes patients in the outpatient unit at RSUD R. Syamsudin, SH. Kota Sukabumi. This non-experimental study uses a descriptive design by reviewing the medical records of outpatients from the pharmacy department. Random blood glucose levels and medication costs are the parameters used. The results of the study showed that the use of the antidiabetic drug glimepiride, which is the most cost-effective drug for type 2 diabetes mellitus patients, demonstrated an average blood glucose reduction of 26.92% for patients using metformin and 22.97% for patients using glimepiride.

Kata Kunci

Cost-effectiveness analysisOral antidiabeticAverage cost effectiveness ratio (ACER)Type 2 diabetes mellitusCost-effectiveness analysisOral antidiabeticAverage cost effectiveness ratio (ACER)Type 2 diabetes mellitus

Cari jurnal yang tepat untuk naskah Anda

MatchMind AI mencocokkan abstrak naskah Anda dengan ribuan jurnal terakreditasi dan menampilkan rekomendasi terbaik beserta alasannya.

Coba MatchMind

Lihat profil lengkap jurnal ini

Waktu review, biaya APC, statistik sitasi, indeksasi Scopus, dan banyak lagi.

Buka Journal Pharmaceutical And Sciences

Artikel ini juga tersedia di situs resmi jurnal.

Cost-efeectivinees analysisis and blood glucose reduction profile of metformin and glimepirid use of type 2 diabetes melitus patient at RSUD R. Syamsudin, SH | Journal Pharmaceutical And Sciences | Publiora